budesonide
Alimentary tract and metabolism (A07)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
pharma · Infertility in women undergoing assisted reproductive technologies (ART) · Intermediate risk, non-muscle invasive bladder cancer
Ferring Pharmaceuticals
Ferring Pharmaceuticals drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
-, St-Prex, 1162, CH, Mumbai HQ
1950 Founded
6,228 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- -, St-Prex, 1162, CH, Mumbai
- Founded
- 1950
- Employees
- 6,228
- Programs
- 13
- Drugs
- 23
- Patents
- 0
Ferring Pharmaceuticals pipeline
Portfolio lens on 23 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Ferring Pharmaceuticals drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records.
-
degarelix
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in Ferring Pharmaceuticals's portfolio. Mechanism: Gonadotropin-releasing hormone receptor antagonist.
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records. Mechanism: Vasopressin receptor agonist.
- Mechanism
- Vasopressin receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records. Molecular target: Follicle-stimulating hormone receptor.
- Target
- Follicle-stimulating hormone receptor
- Mechanism
- Follicle stimulating hormone receptor agonist
-
follitropin alfa
Genito-urinary system and sex hormones (G03)Genito-urinary system and sex hormones (G03) compound in Ferring Pharmaceuticals's portfolio. Molecular target: Follicle-stimulating hormone receptor.
- Target
- Follicle-stimulating hormone receptor
- Mechanism
- Follicle stimulating hormone receptor agonist
-
follitropin delta
Genito-urinary system and sex hormones (G03)Genito-urinary system and sex hormones (G03) compound in Ferring Pharmaceuticals's portfolio. Molecular target: Follicle-stimulating hormone receptor.
- Target
- Follicle-stimulating hormone receptor
- Mechanism
- Follicle stimulating hormone receptor agonist
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records. Molecular target: Polyunsaturated fatty acid 5-lipoxygenase.
- Target
- Polyunsaturated fatty acid 5-lipoxygenase
- Mechanism
- Arachidonate 5-lipoxygenase inhibitor
-
nadofaragene firadenovec
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Ferring Pharmaceuticals's portfolio. Molecular target: Interferon alpha-2.
- Target
- Interferon alpha-2
- Mechanism
- Interferon alpha-2 exogenous gene
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Ferring Pharmaceuticals in public FDA and regional records. Mechanism: Gonadotropin-releasing hormone receptor agonist.
- Mechanism
- Gonadotropin-releasing hormone receptor agonist